Table 1.
Association between SLC23A2 genotypes and the clinical response in 49 patients after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy.
| Total | CR | non-CR | p value | ||
|---|---|---|---|---|---|
| rs2681116 | TT | 9 | 7 | 2 | 0.144 |
| TC | 27 | 11 | 16 | ||
| CC | 13 | 5 | 8 | ||
| rs13037458 | AA | 12 | 9 | 3 | 0.085 |
| AC | 31 | 12 | 19 | ||
| CC | 6 | 2 | 4 | ||
| rs1715364 | TT | 4 | 1 | 3 | 0.758 |
| TC | 25 | 12 | 13 | ||
| CC | 20 | 10 | 10 | ||
| rs4987219 | GG | 2 | 1 | 1 | 0.480 |
| GC | 15 | 5 | 10 | ||
| CC | 32 | 17 | 15 | ||
| rs1110277 | GG | 2 | 0 | 2 | 0.438 |
| GA | 19 | 8 | 11 | ||
| AA | 28 | 15 | 13 |
The rate of the complete response (CR) was 46.9% (23/49). Frequencies in patients with CR were compared with those with non-CR. Significance was assessed using Fisher's exact test.